Healthcare provider profile · identity verified

Catharine Ann Arnold, MD

Rheumatology · GUILFORD, CT · NPI 1306909742

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Prednisone	Prednisone	417	102
Rosuvastatin Calcium	Rosuvastatin Calcium	410	128
Losartan Potassium	Losartan Potassium	379	111
Amlodipine Besylate	Amlodipine Besylate	375	100
Levothyroxine Sodium	Levothyroxine Sodium	366	98
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	335	91
Atorvastatin Calcium	Atorvastatin Calcium	315	88
Gabapentin	Gabapentin	258	74
Methotrexate	Methotrexate Sodium	248	68
Pantoprazole Sodium	Pantoprazole Sodium	237	75
Metoprolol Succinate	Metoprolol Succinate	205	61
Hydrochlorothiazide	Hydrochlorothiazide	197	58
Pravastatin Sodium	Pravastatin Sodium	170	47
Tramadol Hcl	Tramadol Hcl	151	32
Sertraline Hcl	Sertraline Hcl	145	45
Duloxetine Hcl	Duloxetine Hcl	132	34
Alendronate Sodium	Alendronate Sodium	131	42
Lisinopril	Lisinopril	130	41
Trazodone Hcl	Trazodone Hcl	130	29
Omeprazole	Omeprazole	124	32
Fluoxetine Hcl	Fluoxetine Hcl	108	21
Simvastatin	Simvastatin	105	31
Allopurinol	Allopurinol	104	29
Eliquis	Apixaban	99	25
Zolpidem Tartrate	Zolpidem Tartrate	96	26
Doxazosin Mesylate	Doxazosin Mesylate	93	18
Escitalopram Oxalate	Escitalopram Oxalate	92	27
Clonazepam	Clonazepam	89	18
Lorazepam	Lorazepam	88	40
Risedronate Sodium	Risedronate Sodium	85	28
Montelukast Sodium	Montelukast Sodium	84	27
Atenolol	Atenolol	83	21
Ezetimibe	Ezetimibe	78	22
Famotidine	Famotidine	75	21
Albuterol Sulfate Hfa	Albuterol Sulfate	74	20
Meloxicam	Meloxicam	74	23
Potassium Chloride	Potassium Chloride	74	20
Irbesartan	Irbesartan	73	20
Synthroid	Levothyroxine Sodium	66	19
Furosemide	Furosemide	63	21
Metformin Hcl Er	Metformin Hcl	60	19
Celecoxib	Celecoxib	58	15
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	58	17
Olmesartan Medoxomil	Olmesartan Medoxomil	55	17
Alprazolam	Alprazolam	51	16
Leflunomide	Leflunomide	49	14
Ibandronate Sodium	Ibandronate Sodium	48	suppressed
Warfarin Sodium	Warfarin Sodium	47	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	46	13
Bupropion Xl	Bupropion Hcl	44	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	41	11
Doxycycline Hyclate	Doxycycline Hyclate	41	35
Folic Acid	Folic Acid	40	15
Oxycodone Hcl	Oxycodone Hcl	40	12
Ozempic	Semaglutide	40	suppressed
Colchicine	Colchicine	39	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	36	15
Sulfasalazine	Sulfasalazine	35	11
Amitriptyline Hcl	Amitriptyline Hcl	33	suppressed
Valsartan	Valsartan	33	12
Citalopram Hbr	Citalopram Hydrobromide	32	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	31	27
Breo Ellipta	Fluticasone/Vilanterol	29	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	29	suppressed
Humira(Cf) Pen	Adalimumab	29	suppressed
Ketoconazole	Ketoconazole	28	17
Cephalexin	Cephalexin	27	21
Lovastatin	Lovastatin	27	suppressed
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	26	suppressed
Ropinirole Hcl	Ropinirole Hcl	26	suppressed
Actemra	Tocilizumab	25	suppressed
Diclofenac Sodium	Diclofenac Sodium	25	suppressed
Enbrel	Etanercept	25	suppressed
Enbrel Sureclick	Etanercept	25	suppressed
Raloxifene Hcl	Raloxifene Hcl	25	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	25	suppressed
Estradiol	Estradiol	24	suppressed
Humira(Cf)	Adalimumab	24	suppressed
Memantine Hcl	Memantine Hcl	24	suppressed
Ibuprofen	Ibuprofen	22	suppressed
Sulfasalazine Dr	Sulfasalazine	21	suppressed
Telmisartan	Telmisartan	21	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	20	suppressed
Fluticasone Propionate	Fluticasone Propionate	20	suppressed
Xeljanz Xr	Tofacitinib Citrate	20	suppressed
Buspirone Hcl	Buspirone Hcl	19	suppressed
Naproxen	Naproxen	19	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Meclizine Hcl	Meclizine Hcl	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	11
Tamsulosin Hcl	Tamsulosin Hcl	17	suppressed
Topiramate	Topiramate	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	16	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	16	suppressed
Metformin Hcl	Metformin Hcl	16	suppressed
Nebivolol Hcl	Nebivolol Hcl	16	suppressed
Lansoprazole	Lansoprazole	15	suppressed
Nifedipine Er	Nifedipine	15	suppressed
Nystatin	Nystatin	15	suppressed
Ondansetron Odt	Ondansetron	15	suppressed
Methenamine Hippurate	Methenamine Hippurate	14	suppressed
Ondansetron Hcl	Ondansetron Hcl	14	suppressed
Dotti	Estradiol	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	12
Actemra Actpen	Tocilizumab	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	12
Gemtesa	Vibegron	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Prolia	Denosumab	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Amoxicillin	Amoxicillin	11	11
Azithromycin	Azithromycin	11	11
Carvedilol Er	Carvedilol Phosphate	11	suppressed
Myrbetriq	Mirabegron	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error